Featured resident: CeleCor Therapeutics

We are continuing the development of RUC-4, a novel small molecule inhibitor of the platelet αIIbβ3 receptor, designed to be easily administered subcutaneously by auto-injector to facilitate its use as the first point of contact treatment for myocardial infarction (STEMI). 

Area of focus: Therapeutics/Cardiology
Commencement Date: May 15, 2017
Location: JLABS @ San Diego